Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Pharmacoeconomics|March 31, 2018
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalAngela Stainthorpe, Janette Greenhalgh, Adrian Bagust, et al.
Pharmacoeconomics|November 28, 2017
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Ahmed Abdulla, Adrian Bagust, et al.
Pharmacoeconomics|September 13, 2014
Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisalJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Health Technology Assessment (Winchester, England)|April 22, 2015
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysisJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Pharmacoeconomics|April 12, 2013
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisalJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Health Technology Assessment (Winchester, England)|January 15, 2020
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluationNigel Fleeman, Rachel Houten, Adrian Bagust, et al.
Pharmacoeconomics|March 20, 2017
Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Adrian Bagust, Angela Boland, et al.
Pharmacoeconomics|October 5, 2011
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisalRumona Dickson, Adrian Bagust, Angela Boland, et al.
Health Technology Assessment (Winchester, England)|July 3, 2015
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluationJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Pageof 3